成都先导举行首届投资者开放日 解码万亿化合物库价值

Core Insights - Chengdu Xian Dao is a leading company in the field of new molecular discovery, with a core technology platform that is its competitive advantage [2] - The company has the largest publicly known DNA-encoded compound library (DEL) globally, exceeding one trillion molecules, which has enabled over 1,000 commercial R&D projects for more than 600 clients worldwide [2] - The recent investor open day highlighted the dual innovation driven by DEL and AI drug discovery (AIDD), showcasing the company's commitment to expanding its application boundaries in complex drug targets [2][3] Technology and Innovation - The DEL technology has become a key tool for exploring first-in-class (FIC) drug targets, with the company expanding its DEL library to include protein degradation compounds, linear peptides, and cyclic peptides [2] - The HAILO platform integrates DEL, AI, and automation technologies to enhance molecular optimization efficiency through a high-throughput DMTA (Design-Synthesize-Test-Analyze) cycle [3] - The company is advancing its differentiated pipeline, with promising results from its self-developed drug HG146 for treating recurrent or metastatic adenoid cystic carcinoma and the preclinical candidate HGC290 for targeting IL-17A/AF [3] Future Development - The company aims to further explore the value potential of its trillion-level "seed library," enhance innovation capabilities, and expand the application boundaries of its core technology platforms [4] - Chengdu Xian Dao is focused on accelerating the advancement of its self-developed pipeline and collaborative projects to provide more efficient and intelligent new molecular solutions for the global pharmaceutical industry [4]